Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor–Positive, <i>ERBB2</i>-Negative Metastatic Breast CancerElisabetta Munzone, L. J. Blacher, Meredith M. Regan et al.|JAMA Oncology|2023Cited by 37
Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2− Breast Cancer: A Systematic ReviewG Grazia, Mario Giuliano, Lucia Del Mastro et al.|Cancers|2025Cited by 6
Early prediction of endocrine responsiveness in ER+/HER2 negative MBC: Pilot study with 18F-fluoroestradiol (18F-FES) CT/PET.Alessandra Gennari, Nadia Harbeck, Étienne Brain et al.|Journal of Clinical Oncology|2023Cited by 2
Abstract P1-11-13: DE-REAL: ITALIAN MULTICENTER EXPERIENCE OF TRASTUZUMAB DERUXTECAN IN A REAL WORLD SETTINGAndrea Botticelli, Alessandra Fabi, Simone Scagnoli et al.|Cancer Research|2023Cited by 1
36P PROUDER-BC: PROsigna in UnDer-50-year-old patients (pts) with endocrine receptor-positive (ER+) breast cancer (BC) for chemotherapy (CT) prescriptionFrancesco Schettini, G Grazia, Vincenzo Di Lauro et al.|ESMO Open|2025Cited by 0